Want to see MEDS full AI Analyst Report?
Top Page
DataMeds AI
(NASDAQ:MEDS)
Select Model
Select Model
Rating:42Neutral
Price Target:
$0.92
▼(-3.96% Downside)
Action:Reiterated
Date:08/29/26
The score is weighed down primarily by severe deterioration in financial performance (sharp revenue contraction, extremely negative margins, persistent cash burn) and a stressed balance sheet with negative equity and significant debt. Technical indicators also reflect a sustained downtrend (below key moving averages with negative MACD), with only oversold signals (low RSI/Stochastic) offering limited near-term support. Valuation provides little support due to losses (negative P/E) and no dividend yield data.
Positive Factors
Historical Revenue Base
Historical revenue generation and 2024 gross profitability show the company has had an operating base and some prior ability to sell products above cost. This provides a foundation for restructuring, although current results indicate that capability is not presently intact.
Negative Factors
Severe Revenue and Margin Deterioration
The sharp revenue contraction and deeply negative gross margin indicate that scale, pricing, and cost absorption have deteriorated together. Unless the cost structure is reset, weaker sales can continue producing disproportionate losses and undermine the viability of the business model.
Read all positive and negative factors
Positive Factors
Negative Factors
Historical Revenue Base
Historical revenue generation and 2024 gross profitability show the company has had an operating base and some prior ability to sell products above cost. This provides a foundation for restructuring, although current results indicate that capability is not presently intact.
Read all positive factors
DataMeds AI (MEDS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$2.78M
Dividend YieldN/A
Average Volume (3M)514.13K
Price to Earnings (P/E)―
Beta (1Y)0.43
Revenue Growth-78.16%
EPS Growth-15.07%
CountryUS
Employees31
SectorGeneral
Sector StrengthN/A
IndustryMedical - Distribution
Share Statistics
EPS (TTM)N/A
Shares Outstanding3,061,919
10 Day Avg. Volume1,175,123
30 Day Avg. Volume514,135
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-2.28
Price to Sales (P/S)1.22
P/FCF Ratio-2.61
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
DataMeds AI Business Overview & Revenue Model
Company Description
DataMEDS AI is a Health IT company focused on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units. The company incorporates its artificial intelligence platform EinsteinRx™ and blockchain-enab...
DataMeds AI Financial Statement Overview
Summary
Income Statement
8
Very Negative
Balance Sheet
18
Very Negative
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 8.02M | 23.34M | 18.13M | 0.00 | 32.78M |
| Gross Profit | -9.68M | -9.64M | 1.77M | 0.00 | 5.75M |
| EBITDA | -56.41M | -93.48M | -4.91M | -2.88M | -369.03K |
| Net Income | -88.28M | -101.27M | -6.86M | -2.90M | -2.74M |
Balance Sheet | |||||
| Total Assets | 32.76M | 30.46M | 57.33M | 338.36K | 0.00 |
| Cash, Cash Equivalents and Short-Term Investments | 2.46M | 42.57K | 1.03M | 1.36K | 0.00 |
| Total Debt | 32.62M | 24.77M | 25.11M | 700.00K | 0.00 |
| Total Liabilities | 52.26M | 42.91M | 50.60M | 3.24M | 5.25K |
| Stockholders Equity | -19.50M | -12.45M | 6.73M | -2.90M | -5.25K |
Cash Flow | |||||
| Free Cash Flow | -13.59M | -10.86M | -1.60M | -349.14K | 0.00 |
| Operating Cash Flow | -13.74M | -10.86M | -1.22M | -349.14K | 0.00 |
| Investing Cash Flow | -923.70K | -881.53K | 469.07K | 0.00 | 0.00 |
| Financing Cash Flow | 16.70M | 10.75M | 1.78M | 350.50K | 0.00 |
DataMeds AI Risk Analysis
DataMeds AI disclosed 64 risk factors in its most recent earnings report. DataMeds AI reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
DataMeds AI Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $105.86B | 24.19 | -194.39% | 0.37% | 8.84% | 48.98% | |
70 Outperform | $63.15B | 24.48 | 106.43% | 0.73% | 5.09% | 38.10% | |
69 Neutral | $10.01B | 25.96 | 12.37% | ― | 6.49% | 10.41% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
44 Neutral | $93.05M | -0.31 | 63.40% | 0.02% | -69.68% | 74.88% | |
42 Neutral | $2.78M | -0.02 | 877.58% | ― | -78.16% | -15.07% |
* General Sector Average
MEDS
DataMeds AI
0.92
-78.58
-98.85%
COR
Cencora
330.95
35.34
11.96%
HSIC
Henry Schein
89.81
22.07
32.58%
MCK
McKesson
907.99
213.74
30.79%
ACH
Accendra Health
1.21
-4.17
-77.51%
HKPD
Hong Kong Pharma Digital Technology Holdings Ltd.
0.13
-1.09
-89.59%
DataMeds AI Corporate Events
Business Operations and StrategyDividends
DataMeds AI Announces Token-Based Shareholder Distribution Plan
Neutral
Aug 14, 2026
Datavault AI Inc. plans a voluntary one-time distribution of Dream Bowl 2026 Meme Coin tokens to record holders of DataMEDS AI common stock as of August 7, 2026, with fifty tokens allocated per share. The payment is scheduled to begin on September...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.